Condition: Breast Cancer · Sponsor: NSABP Foundation Inc
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of breast cancer cells, either by killing the cells or by stopping them from dividing. Giving the drugs in different combinations may kill more breast cancer cells. Giving combination chemotherapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in treating women with non-metastatic breast cancer.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Providence Alaska Medical Center | Anchorage, Alaska, United States | — |
| Arizona Oncology Associates-Biltmore Cancer Center | Phoenix, Arizona, United States | — |
| Premiere Oncology of Arizona | Scottsdale, Arizona, United States | — |
| Sedona Medical Center | Sedona, Arizona, United States | — |
| Arizona Oncology Associates | Tucson, Arizona, United States | — |
| NEA Baptist Clinic-Matthews | Jonesboro, Arkansas, United States | — |
| Kaiser Anaheim Medical Center | Anaheim, California, United States | — |
| Kaiser Permanente-Deer Valley Medical Center | Antioch, California, United States | — |
| Kaiser Permanente Medical Group - Baldwin Park | Baldwin Park, California, United States | — |
| Kaiser Foundation Hospital | Bellflower, California, United States | — |
| Providence Saint Joseph Medical Center | Burbank, California, United States | — |
| East Bay Radiation Oncology Center | Castro Valley, California, United States | — |
+ 903 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.